TITLE

Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate: A Chart Review of Spanish Adults with Attention-Deficit Hyperactivity Disorder

AUTHOR(S)
Ramos-Quiroga, Josep Antoni; Bosch, Rosa; Castells, Xavier; Valero, Sergi; Nogueira, Mariana; Gómez, Nuria; Yelmo, Silvia; Ferrer, Marc; Martínez, Yolanda; Casas, Miguel
PUB. DATE
May 2008
SOURCE
CNS Drugs;2008, Vol. 22 Issue 7, p603
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND: The potential advantages of osmotic-release oral system (OROS) methylphenidate (Concerta) over immediate-release (IR) methylphenidate (Rubifen) in adults with attention-deficit hyperactivity disorder (ADHD), with respect to medication adherence, effectiveness and tolerability, are yet to be determined. The switch from IR methylphenidate to OROS methylphenidate was associated with a statistically significant improvement in all items of the SMAQ questionnaire. OROS methylphenidate was more effective than IR methylphenidate (p = 0. 0005) in reducing symptoms of ADHD. The percentage of responders was 28. 6% with IR methylphenidate and 91. 4% with the OROS formulation (p = 0. 0005). OROS methylphenidate was preferred by 97% of patients. The most common adverse events for each formulation were dry mouth (30% IR methylphenidate) and mood instability (31% OROS methylphenidate). No patients stopped treatment with methylphenidate because of adverse events. OBJECTIVE: To compare the adherence, effectiveness and tolerability of OROS methylphenidate versus IR methylphenidate in adults with ADHD. It was hypothesized (after data collection) that adherence and effectiveness would be higher with OROS methylphenidate than with the IR formulation. The switch from IR methylphenidate to OROS methylphenidate was associated with a statistically significant improvement in all items of the SMAQ questionnaire. OROS methylphenidate was more effective than IR methylphenidate (p = 0. 0005) in reducing symptoms of ADHD. The percentage of responders was 28. 6% with IR methylphenidate and 91. 4% with the OROS formulation (p = 0. 0005). OROS methylphenidate was preferred by 97% of patients. The most common adverse events for each formulation were dry mouth (30% IR methylphenidate) and mood instability (31% OROS methylphenidate). No patients stopped treatment with methylphenidate because of adverse events. STUDY DESIGN: A chart review was carried out from April 2004 until April 2005. The switch from IR methylphenidate to OROS methylphenidate was associated with a statistically significant improvement in all items of the SMAQ questionnaire. OROS methylphenidate was more effective than IR methylphenidate (p = 0. 0005) in reducing symptoms of ADHD. The percentage of responders was 28. 6% with IR methylphenidate and 91. 4% with the OROS formulation (p = 0. 0005). OROS methylphenidate was preferred by 97% of patients. The most common adverse events for each formulation were dry mouth (30% IR methylphenidate) and mood instability (31% OROS methylphenidate). No patients stopped treatment with methylphenidate because of adverse events. SETTING: Adult ADHD outpatient program in a general hospital in Spain. The switch from IR methylphenidate to OROS methylphenidate was associated with a statistically significant improvement in all items of the SMAQ questionnaire. OROS methylphenidate was more effective than IR methylphenidate (p = 0. 0005) in reducing symptoms of ADHD. The percentage of responders was 28. 6% with IR methylphenidate and 91. 4% with the OROS formulation (p = 0. 0005). OROS methylphenidate was preferred by 97% of patients. The most common adverse events for each formulation were dry mouth (30% IR methylphenidate) and mood instability (31% OROS methylphenidate). No patients stopped treatment with methylphenidate because of adverse events. PATIENTS: Seventy adults with ADHD who met DSM-IV-TR criteria and who did not have any other current major psychiatric disorder. The switch from IR methylphenidate to OROS methylphenidate was associated with a statistically significant improvement in all items of the SMAQ questionnaire. OROS methylphenidate was more effective than IR methylphenidate (p = 0. 0005) in reducing symptoms of ADHD.…
ACCESSION #
32686418

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics